RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Molecular Pharmacology (USA) - Stock

Molecular Pharmacology (USA) Debt 2024

Molecular Pharmacology (USA) Debt

0 USD

Ticker

MLPH

ISIN

US60852T1097

WKN

A0HHDZ

In 2024, Molecular Pharmacology (USA)'s total debt was 0 USD, a 0% change from the 0 USD total debt recorded in the previous year.

Molecular Pharmacology (USA) Aktienanalyse

What does Molecular Pharmacology (USA) do?

The company Molecular Pharmacology (USA) Ltd is a biotechnology company based in the United States that specializes in the research and development of innovative drugs for the treatment of diseases. It was founded in Illinois in 2000 and has since been headquartered in Lincolnshire, Illinois. Molecular Pharmacology (USA) Ltd focuses on producing high-quality pharmaceutical agents that work at the molecular level and target specific objectives. Using advanced technologies such as computer-aided drug design (CADD) and high-throughput screening (HTS), the company identifies new drug candidates that specifically target certain diseases. The main focus of Molecular Pharmacology (USA) Ltd is the development of drugs for the treatment of cancer, inflammation, and metabolic diseases. In recent years, the company has also focused on other diseases, such as neurological disorders. Molecular Pharmacology (USA) Ltd divides its offerings into various areas to meet the diverse needs of customers. One of these areas is the provision of active ingredients for the pharmaceutical industry. The company provides high-quality pharmaceutical agents that can be used by other companies for further drug development and production. Another area is the development of its own drugs that can be used to combat various diseases. Molecular Pharmacology (USA) Ltd focuses on the identification and development of new drug candidates that specifically target the causes of diseases and enable effective treatment. Molecular Pharmacology (USA) Ltd also offers services to support customers in the identification and characterization of drug candidates. Customers can rely on the company's experience and expertise to support them in the development of new drugs. Some of the key products of Molecular Pharmacology (USA) Ltd include small molecules, antibodies, peptides, and natural compounds. These provide a high level of efficacy and safety in combating various diseases and thus serve as an important foundation for the development of new drugs. In recent years, Molecular Pharmacology (USA) Ltd has also increased its investments in collaboration with other companies and research institutions. This aims to leverage synergies to jointly identify and develop new drug candidates. An example of this is the collaboration with universities and research institutions specializing in the study of certain diseases. In summary, Molecular Pharmacology (USA) Ltd is a renowned biotechnology company that specializes in the research and development of innovative drugs for the treatment of diseases. The company divides its offerings into various areas and provides services to other companies and research institutions. Molecular Pharmacology (USA) Ltd is thus an important player in the field of drug development and contributes to saving many lives. Molecular Pharmacology (USA) ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Molecular Pharmacology (USA)'s Debt Structure

Molecular Pharmacology (USA)'s total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Molecular Pharmacology (USA)'s debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Molecular Pharmacology (USA)’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Molecular Pharmacology (USA)’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Molecular Pharmacology (USA) Stock

What is the debt of Molecular Pharmacology (USA) this year?

Molecular Pharmacology (USA) has a debt level of 0 USD this year.

What was the debt of Molecular Pharmacology (USA) compared to the previous year?

The debt of Molecular Pharmacology (USA) has increased by 0% compared to the previous year dropped.

What are the consequences of high debt for investors in Molecular Pharmacology (USA)?

High debt can pose a risk for investors of Molecular Pharmacology (USA), as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Molecular Pharmacology (USA)?

Low debt means that Molecular Pharmacology (USA) has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Molecular Pharmacology (USA) affect the company?

An increase in debt of Molecular Pharmacology (USA) can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Molecular Pharmacology (USA) affect the company?

A reduction in debt of Molecular Pharmacology (USA) can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Molecular Pharmacology (USA)?

Some factors that can influence the debt of Molecular Pharmacology (USA) include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Molecular Pharmacology (USA) so important for investors?

The debts of Molecular Pharmacology (USA) are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Molecular Pharmacology (USA) take to change the debt?

To change the debt, Molecular Pharmacology (USA) can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Molecular Pharmacology (USA) pay?

Over the past 12 months, Molecular Pharmacology (USA) paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Molecular Pharmacology (USA) is expected to pay a dividend of 0 USD.

What is the dividend yield of Molecular Pharmacology (USA)?

The current dividend yield of Molecular Pharmacology (USA) is .

When does Molecular Pharmacology (USA) pay dividends?

Molecular Pharmacology (USA) pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Molecular Pharmacology (USA)?

Molecular Pharmacology (USA) paid dividends every year for the past 0 years.

What is the dividend of Molecular Pharmacology (USA)?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Molecular Pharmacology (USA) located?

Molecular Pharmacology (USA) is assigned to the '-' sector.

Wann musste ich die Aktien von Molecular Pharmacology (USA) kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Molecular Pharmacology (USA) from 7/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/3/2024.

When did Molecular Pharmacology (USA) pay the last dividend?

The last dividend was paid out on 7/3/2024.

What was the dividend of Molecular Pharmacology (USA) in the year 2023?

In the year 2023, Molecular Pharmacology (USA) distributed 0 USD as dividends.

In which currency does Molecular Pharmacology (USA) pay out the dividend?

The dividends of Molecular Pharmacology (USA) are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Molecular Pharmacology (USA)

Our stock analysis for Molecular Pharmacology (USA) Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Molecular Pharmacology (USA) Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.